Cell Cryopreservation Market, By Product Type (Cryoprotectant Agents and Equipment), By Application (Stem Cells, Oocytes and Embryotic cells, Sperm Cells, Hepatocytes, Others), By End User (Biopharmaceutical & Pharmaceutical Companies, Research Institutes, Biobank, IVF clinics, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Jul 2024

Code : CMI1698

Pages :192

Formats :

Excel and PDF

Industry : Biotechnology

Key Developments

In June 2023, BioLife Solutions, Inc., a prominent provider of bioproduction tools and services for cell and gene therapy, introduced a new large-capacity controlled-rate freezer (CRF) as part of its expanded product line. This addition, which now includes three different form factors, addresses a significant demand from customers seeking increased production capacity for cell therapies on tabletop freezers.
In 2022, AMSBIO, a leading provider of quality life science research reagents and services. launched 'STEM-CELLBANKER EX,' an innovative cryopreservation product designed to accelerate the development of cell therapy products. This chemically defined cryopreservation medium includes inactive ingredients approved for intravenous use, providing a premium solution for preserving stem cells. This advancement is poised to significantly enhance research and development in the field of cell therapy.
In May 2022, Bristol Myers Squibb, global biopharma company received European Commission approval for Breyanzi, a CAR T cell therapy targeting CD19, to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more prior treatments. This authorization applies to all European Union member states.
In July 2020, Kite, a biotechnology company, gained FDA accelerated approval for Tecartus, another CAR T cell therapy, for adult patients with relapsed or refractory mantle cell lymphoma (MCL). Tecartus was approved following a priority review and FDA Breakthrough Therapy Designation, based on results from the ZUMA-2 study. The study showed a 87% response rate to a single infusion of Tecartus, with 62% achieving a complete response. Notably, 18% experienced Grade 3 or higher cytokine release syndrome (CRS) and 37% had Grade 3 or higher neurologic toxicities among those evaluated for safety.